Illinois Biotechnology Industry Organization Makes Notable Additions to Board of Directors

Senior Executives from Leading International Companies Bring Great Depth to Leadership Team

CHICAGO--(BUSINESS WIRE)--The Illinois Biotechnology Industry Organization (iBIO) today announced the election of new additions to its Board of Directors. The new Board members, who include senior executives, policy, and investment experts from globally recognized corporations, add depth and prestige to an already-strong lineup of medical, agricultural, and industrial biotech representation.

Joining iBIO's Board are Daniel Brennan of Lundbeck US, Jamie Oldani of Eli Lilly, Susanne Resatz of Vetter Development Services USA and Geeta Vemuri of Baxter Ventures.

Daniel Brennan is Vice President and General Manager of Neurology and Business Development for Lundbeck US. The Neurology business unit is responsible for commercializing several products, including Xenazine™ (tetrabenazine, Huntington Disease), Sabril™ (vigabatrin, refractory partial complex seizures), Onfi™ (clobazam, Lennox-Gastaut disease), and Northera™ (droxidopa, neurogenic orthostatic hypotension as a result of neurological disorders and other means). The Neurology Business Unit at Lundbeck US generates over $500 million in annual sales.

Jamie Oldani serves as the Midwest Director of State Government Affairs for Eli Lilly and Company. The global pharmaceutical research-based company, headquartered in Indianapolis, Indiana, has a heritage more than 135 years strong, with approximately 39,000 employees worldwide. Jamie represents the company in public, private, and professional forums addressing policy issues involving the healthcare industry. She is responsible for monitoring the legislative, regulatory, administrative and political processes that affect government funded healthcare programs, as well as their impact upon industry. With years of experience and a network of partners, she serves as a strong advocate for patients and a robust healthcare delivery system.

Susanne Resatz, Ph.D., President of Vetter Development Services USA, Inc., heads Vetter's clinical manufacturing facility in suburban Chicago, Illinois. Vetter is an independent international contract development and manufacturing organization (CDMO), headquartered in Ravensburg, Germany, with a clientele that includes the world's leading pharmaceutical and biotechnology companies. Its Chicago facility is the company's first U.S. site, and provides development support and aseptic manufacturing for preclinical through Phase IIb injectables, primarily complex biologics.

Geeta Vemuri joined Baxter in January 2012 as Vice President, Head of Baxter Ventures, the corporation's $200 million venture fund. Prior to joining Baxter, she was a General Partner at Quaker Partners, where she led investments in biopharmaceutical and healthcare companies and was an integral part of the team raising capital for the funds. Dr. Vemuri's role in building and mentoring portfolio companies has facilitated successful exits through acquisitions and Initial Public Offerings.

"Geeta, Susanne, Jamie and Daniel bring great experience to our iBIO Board," said David Miller, President & CEO of the organization. "The diversity of their expertise reflects the strengths of the greater Chicago and Midwest regions. We are proud to engage with executives of their caliber, and grateful for their willingness to help lead our community's development."

The Illinois Biotechnology Industry Organization

iBIO's mission is to make Illinois and the surrounding Midwest one of the world's top life sciences centers: a great place to do business and a great place to grow technology ventures.

iBIO, working on its own and through valued partners

Promotes sound public policy at the local, state and federal levels;
Improves our region's ability to create, attract and retain businesses
Orchestrates industry involvement to help solve America's math and science education crisis
Builds community by providing opportunities to connect and engage with the industry
We thereby contribute to the well-being of people worldwide while creating new jobs, attracting firms to the region and generating prosperity.

iBIO's Leadership Sponsors are AbbVie, Astellas US, and Takeda Pharmaceuticals North America.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.